data:image/gif;base64,R0lGODlhAQABAAD/ACwAAAAAAQABAAACADs=

INNOVOTEX INNOVATION

INNOVOTEX is an oncology therapeutic company developing its proprietary platform of uniquely designed novel assets. We identified a lead clinical candidate, NOVO-111, that induces ribosomal biosynthesis stress to activate wt-p53 and circumvent platinum resistance in wt-p53 refractory cancers.

About Us

Dr. Jonathan Arambula

Dr. Jonathan Arambula

Dr. Jonathan Arambula

Co-founder, CEO & Director

Dr. Jonathan Sessler

Dr. Jonathan Arambula

Dr. Jonathan Arambula

Co-founder, Director & 

Head SAB

Dr. Krystle Karoscik

Dr. Jonathan Arambula

Dr. Krystle Karoscik

Co-founder and COO

Dr. Tarak Mody

Dr. Jonathan Arambula

Dr. Krystle Karoscik

Director

Press Releases

July 2024

Industry Leader Dr. Tarak Mody Joins INNOVOTEX Board of Directors

July 2024

An Innovative, Targeted Approach to Cancer Treatment

October 2022

Copyright © 2024 InnovoTex Inc. - All Rights Reserved.

Contact: jarambula@innovotexinc.com

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept